Transcranial Magnetic Stimulation (TMS)

Healthcare · §664

For a depression that won't budge after two or three antidepressants, a six-week course of TMS — daily clinic visits, magnetic pulses to the frontal lobe, awake the whole time, no anesthesia — gives roughly one in three patients a real shot at remission. It's been FDA-cleared for depression since 2008, also cleared for OCD and for help quitting cigarettes; insurance covers the depression use for most US patients,. Mainstream medicine, not the experimental edge — and most people who'd benefit have never been offered it.

Decide · Course Evidence Moderate Chapter Healthcare

The whole story is depression that won't shift on pills. Remission for roughly one in three treatment-resistant patients is a categorically different result from another antidepressant that probably won't work either. Sticker price is real — about $10,000–$18,000 for a full course — but insurance carries it for the indicated patient. The cost that doesn't go away is daily clinic visits, weekdays, for four to six weeks. OCD and cigarette dependence are the two other FDA-cleared uses; access for those is patchier.

A coil sits against your scalp, about where your hairline meets your forehead on the left side. It carries a pulsed magnetic field strong enough to reach a few centimeters into the brain — about 1.5 cm for a standard figure-eight coil, a bit deeper for the H-shaped coils used in OCD and smoking protocols Rossi et al. 2021. The magnetic pulse passes through the skull without resistance and induces a small electrical current in the cortex underneath. Repeated thousands of times across a session, this nudges that patch of brain to fire more (or less, depending on the rhythm) than it would on its own.

For depression, the patch in question is the left dorsolateral prefrontal cortex — a region that's reliably under-active on brain scans during a depressed episode. Excite it daily for a few weeks and the dampening effect propagates down to deeper emotional-regulation circuits that the magnetic field can't reach directly Lefaucheur et al. 2020. For OCD, the target is a different patch — the medial frontal cortex, the area implicated in the compulsion loop Carmi et al. 2019. For smoking, it's the addiction-related circuitry around the insula, with the patient watching smoking imagery just before stimulation so the circuit is actively engaged when it gets hit Zangen et al. 2021.

You're awake the entire time. The pulses make a rhythmic clicking sound — earplugs are required — and feel like firm rapid tapping on the scalp. You can talk, read, listen to music. Most clinics have you back in your car twenty minutes after stimulation ends. No drugs, no anesthesia, no down day.

Does it actually work?

For treatment-resistant depression — the indication this entry mostly speaks to — yes, with honest caveats about who and how much. In the pooled trial data across roughly 1,400 patients, a course of TMS produces a meaningful drop in depression symptoms in about three out of ten people, and full remission in about one in five — versus one in twenty or so on sham Berlim et al. 2014. In real-world clinics where patients tend to receive longer courses and fewer of them are at the maximally-resistant end, the response numbers run higher — closer to half show meaningful improvement, with about one in three reaching remission Carpenter et al. 2012. Both numbers matter: the controlled trial is the floor, the clinic data is the ceiling, the truth for any given patient is somewhere between.

The numbers don't sound dramatic on their own. They land differently when you put them next to the alternative. The largest naturalistic study of sequential antidepressant trials in the US — STAR*D — showed that by the third medication someone tries, remission rates have dropped to roughly one in seven; by the fourth, one in eight Rush et al. 2006. TMS's roughly one-in-three remission for someone in that spot isn't a small effect against a strong comparator; it's a notably better shot than what the medication ladder has left to offer.

For OCD, the signal is real but smaller. The pivotal multicenter trial of deep TMS for treatment-resistant OCD showed a Y-BOCS symptom drop of about six points in 38% of the active group versus 11% on sham Carmi et al. 2019. That earned the 2018 FDA clearance FDA 2018. Most responders still have meaningful OCD afterwards — this is augmentation, not cure. Exposure-response prevention therapy and an SSRI remain the first two steps; TMS sits later in the OCD ladder.

For smoking, the pivotal trial of deep TMS over six weeks produced a 4-week continuous quit rate of 28% active versus about 12% sham, with about 19% still abstinent at six months from the start Zangen et al. 2021. That's competitive with or better than varenicline in this hard-to-quit population. The catch is access: the smoking indication earned clearance in 2020 FDA 2020 but very few US clinics actually offer it, and almost no insurance pays for it.

Who this is actually for

The indicated and reimbursable population for depression in the US is adults with major depressive disorder who have failed at least one — and in most insurance plans two — antidepressant trials at a reasonable dose for a reasonable time. The Canadian guidelines list it as first-line after one medication failure Milev et al. 2016; the European consensus says the same Lefaucheur et al. 2020; the US consensus statement from clinicians who actually run these treatments says it shouldn't be the last thing tried McClintock et al. 2018. If you're on antidepressant number three after a couple years of partial relief, you are squarely in the indicated population.

For OCD, the audience is adults with treatment-resistant OCD — meaning at least one well-conducted exposure-response prevention course and at least one SSRI trial have not produced sufficient relief. For smoking cessation, the audience is adults who have chronically smoked at least ten cigarettes a day and have made at least one serious quit attempt that didn't stick.

Older adults respond, with a small caveat: historically, response rates above age 60 ran somewhat lower, partly because the brain pulls slightly inward away from the scalp with age and the magnetic field has further to travel. Modern protocols use higher intensity to compensate, and the gap has narrowed Lisanby et al. 2009. Adolescent depression — under 18 — is an emerging area with smaller trials and not-yet-routine insurance coverage; effect signals look similar to adults Croarkin et al. 2021.

Why this matters now

Picture the version of you that has been on three antidepressants over the last three years. The first one helped for a while. The second one didn't really. The third has you at maybe seventy percent of where you'd like to be, with side effects you don't love. Your psychiatrist is now talking about a fourth medication or an augmenter — lithium, an antipsychotic, a thyroid hormone — and you know roughly what each will cost you in side effects.

The unspoken number under this conversation: at this point on the medication ladder, your odds of full remission from the next pill are about one in seven, and they get worse from there Rush et al. 2006. Not zero. But the version of your week where mornings are flat and conversations require willpower has a decent chance of still being the version of your week in another two years. People around you who knew the pre-depression you have mostly stopped expecting them back. Your partner has learned to schedule plans without you on the worse days, which is a kindness that quietly becomes a permanent arrangement. The next antidepressant after three failures is statistically not the thing that breaks this.

TMS is the option in this picture that most clinicians outside major academic centers don't bring up early. It is the standard-of-care next step in the guidelines that handle this scenario explicitly Milev et al. 2016. The reader who pushes for it — or asks their psychiatrist for a referral — is asking for the high-yield move at exactly the point on the ladder where pharmacology starts paying out in pennies.

What a course actually looks like

You arrive at a clinic on a Monday morning. The first session is the longest, maybe an hour, because the technician needs to find your motor threshold first: a few test pulses over the motor strip until your thumb twitches reliably. Treatment intensity gets set at 120% of that. The coil position over your left forehead gets marked. Then the actual stimulation starts — for the standard high-frequency depression protocol, that's about 37 minutes of pulse trains in a steady rhythm.

Then you come back tomorrow. And the day after. Five days a week, for four to six weeks, typically thirty to thirty-six sessions total. Many modern clinics use the shorter theta-burst version of the protocol, which compresses the chair time to about three minutes per visit while producing the same results Blumberger et al. 2018.

A newer five-day accelerated protocol — Stanford Neuromodulation Therapy, or SNT — packs ten short sessions per day for five days straight, with brain-scan-guided targeting individualized per patient. It earned FDA clearance in 2022 after a small sham-controlled trial reported remission rates much higher than standard courses Cole et al. 2022. The catch: the trial enrolled fewer than thirty people, and the protocol is offered at a small handful of centers. The mainstream evidence-base is still the daily-for-six-weeks course; the accelerated version is reasonable when timing genuinely matters (acute suicidality, or someone who can't do six weeks of daily appointments) but it isn't yet the standard.

The OCD course runs about six weeks with daily deep-TMS sessions plus a brief symptom-provocation step right before each session — the technician walks you through whatever obsession or trigger your protocol targets, then stimulation starts while the circuit is engaged Carmi et al. 2019. The smoking course is shorter — eighteen sessions over six weeks, with a few minutes of looking at smoking imagery before each session, plus weekly booster sessions for three months after Zangen et al. 2021.

When not to do this

The headline risk people fear is seizure. With modern dosing guidelines and proper screening, the incidence is on the order of one seizure per 30,000 sessions delivered — rare, almost always in patients with one of the risk factors above, and not associated with lasting harm Rossi et al. 2021. Cardiac pacemakers and implanted defibrillators are not automatic deal-breakers; the field falls off rapidly with distance and these devices typically sit well below the coil. Coordinate with your cardiologist.

The everyday side effects are nuisances rather than risks. About a third of patients get some scalp discomfort at the stimulation site; about a third get headaches, usually the kind a normal painkiller handles; a smaller fraction get face-muscle twitching during stimulation that stops when the pulses stop. These almost always settle inside the first week. Notably absent: no memory problems, no sedation, no weight gain, no sexual side effects — the clean side-effect profile is genuinely the best thing TMS has going for it next to its closest alternatives.

What people get wrong

The biggest one: confusing TMS with ECT. They share "applying electricity to the brain for depression" at the surface and almost nothing else. ECT — electroconvulsive therapy — requires general anesthesia, deliberately induces a controlled seizure, has real cognitive side effects (memory gaps in the weeks around treatment, sometimes persisting), and is the standard of care for severe melancholic or psychotic depression. TMS requires no anesthesia, deliberately stays below seizure threshold, has no cognitive side effects, and is the standard for treatment-resistant depression that isn't urgent Mutz et al. 2019. The two are not interchangeable and they're not sequential — they sit at different points on the ladder.

The second one: "isn't this experimental?" It's been FDA-cleared since 2008, longer than several common antidepressants FDA 2008. Medicare covers it. Major commercial insurers cover it. It's in the Canadian, European, and American clinical guidelines as a recommended option after antidepressants fail Milev et al. 2016, Lefaucheur et al. 2020. Confusion comes from how rarely it gets brought up — most primary-care doctors and even some general psychiatrists don't routinely mention it.

The third one: that the patient is unconscious or sedated. You're awake. You can talk between trains of pulses, listen to music, watch a video on your phone. Some clinics put a TV on the wall. You drive yourself home and go to work.

The fourth one is newer and more subtle: the assumption that the five-day SNT/SAINT accelerated protocol is now standard. The early remission numbers from the small Stanford trial were eye-catching but came from fewer than thirty patients, with brain-scan-guided targeting and intensive monitoring not yet replicated outside research-grade centers Cole et al. 2022. Routine TMS — daily for several weeks — is the workhorse with the deep RCT and real-world track record. Accelerated is a reasonable choice for specific situations, not yet the default.

Where it goes wrong

Two-thirds of patients aren't full responders. The honest framing of a TMS course is "decent odds of meaningful improvement, modest odds of full remission, real chance of not much" — much like every depression treatment in this part of the ladder. People who go in expecting a transformation and don't get one feel doubly disappointed; people who go in expecting a coin-flip and land on the responder side feel like they got something real.

Durability is the second honest catch. About half of patients who do respond to an acute course will relapse within twelve months without any maintenance strategy Dunner et al. 2014, Janicak et al. 2010. That sounds bad in isolation; it's roughly the relapse rate for any depression treatment without continuation care. The practical implication is that the course isn't a one-and-done. Continuing your antidepressant after TMS, periodic booster sessions, and a low threshold for a re-induction course at the first sign of return — that's the package, and insurance generally covers re-induction once relapse is documented.

The under-dosed course is a quieter failure mode. Insurance approves twenty sessions, the patient is feeling better at session sixteen, the clinic stops there to save the patient time — and the gain doesn't stick. Real-world data shows the better outcomes are tied to completing the full thirty-plus session course Carpenter et al. 2012. If you're improving mid-course, that is the moment to finish, not to back off.

The under-targeted course is the most technical failure mode. The cheap way to find left dorsolateral prefrontal cortex — measuring 5 cm forward from the motor hotspot — misses the optimal stimulation site by a centimeter or two in patients with atypical brain anatomy. Clinics that use a head-MRI scan to navigate the coil get more consistent positioning; this isn't universal yet. If your initial course doesn't respond and the clinic uses the geometric-rule targeting, asking about MRI-guided positioning for a re-induction is reasonable.

Cost, time, and finding a provider

Cost. Sticker price for a full depression course in the US runs roughly $10,000–$18,000 — about $300–$500 per session times thirty-some sessions. For the indicated patient (major depression, documented failure of two antidepressants), Medicare and most major commercial insurers cover it. Your out-of-pocket is typically the same copays you'd pay for any specialist visit. Insurance approval takes paperwork — your psychiatrist needs to document which medications you tried, at what dose, for how long, and what happened. OCD coverage exists but is more variable plan by plan. Smoking-cessation TMS is largely cash-pay, and at full sticker that's a hard sell against a $30 box of nicotine patches.

Time. Realistically, plan on an hour out of your day, weekdays, for four to six weeks. The chair time itself is short for theta-burst protocols (about three minutes) and longer for standard ten-hertz (about thirty-seven minutes), but travel and check-in dominate either way. People who are working tend to schedule first thing in the morning or right after lunch. The schedule is the real cost of TMS, more than the money.

Finding a provider. Concentrated in mid-to-large cities with academic psychiatry programs or larger group practices. Smaller metros often have one or two clinics and meaningful wait lists. Most clinics will take a referral from any psychiatrist, primary care doctor, or sometimes a self-referral. The Clinical TMS Society maintains a clinic directory; the device manufacturers (NeuroStar, Brainsway, MagVenture) also list partner clinics. If you live rurally, some patients arrange a six-week stay near a city-based clinic — clinics that see this pattern often have local-housing referrals.

The session itself. You sit in a chair like a dental chair. The technician positions the coil, marks it on a swim-cap-style headpiece so daily positioning is reproducible, and starts stimulation. You wear earplugs — the pulses are loud, a hard clicking sound around 100 decibels. The scalp sensation is firm tapping, not pain. Most patients are bored by week two, which is the right kind of boring.

What it feels like when it works

Nothing happens for the first ten or so sessions. Some people get headaches the first week. You go in, you sit, you tap your foot, you go home, you wonder what you're doing.

Then somewhere in week three or four something shifts. The first thing most responders notice isn't joy — it's the absence of the wet-blanket feeling. Getting out of bed in the morning stops being a negotiation. The grocery store isn't a project anymore. Your partner, who's learned to read your mood without asking, stops giving you the careful look at breakfast. A coworker asks what you did this weekend and you have an actual answer because you actually did things this weekend.

By week six, if you're in the responder group, the people around you have started saying it out loud. You seem like yourself. Your sister, who'd been calling to check in every other day for two years, doesn't have to anymore. The friend whose calls you'd been letting roll to voicemail — you call back, and the conversation isn't an effort. Music sounds like music again, not like noise wrapping around something heavy.

The honest version of the timeline: a third of people in this spot get this experience, another quarter get a partial version of it, and the rest don't. For the ones it lands for, the magnitude of the change is the difference between "function is broken" and "function is intact" — which is a different category from the percent-improvement language clinical trials use Carpenter et al. 2012. The improvement holds for months to years for most responders, sometimes drifts back, sometimes needs a re-induction; the people who needed it the most don't, in practice, regret the six weeks of clinic visits.

For OCD, the felt change is more partial — the urges and intrusive thoughts get quieter rather than disappearing, the compulsions you'd been losing hours to take less of your day, you can sit with the discomfort exposure therapy was already teaching you to sit with Carmi et al. 2019. For someone quitting smoking, the cigarette craving stops being the constant background noise it's been for years — not gone, but small enough that the behavioral tools that didn't work before suddenly do Zangen et al. 2021.

Related and worth knowing

If you're researching this because of treatment-resistant depression, the adjacent options worth knowing about — and discussing with your psychiatrist — include ketamine and esketamine (Spravato), which work on a different mechanism and a much faster timeline; electroconvulsive therapy (ECT), which has higher acute remission rates than TMS but a real cognitive cost and an anesthesia requirement; and pharmacologic augmentation strategies like lithium or low-dose atypical antipsychotics. TMS, ketamine, and ECT each occupy a distinct slot — they're not redundant, and many patients end up trying more than one.

If you're researching this because of OCD, the things that come before TMS in the standard ladder are exposure-response prevention therapy done by a properly trained clinician, and adequate-dose SSRI or clomipramine trials. TMS sits later, as augmentation.

If smoking cessation is the question, the first-line tools — varenicline, combination nicotine replacement, bupropion, behavioral coaching — have stronger evidence and dramatically better access than smoking-cessation TMS, which remains a niche option.

Related in the handbook

Helps

— TMS is FDA-cleared for quitting smoking too, aiming pulses at the addiction circuit, though few clinics actually offer it.

Alternatives

— For depression that's failed multiple drugs, TMS and ketamine are the two main next-line options — different mechanisms, similar goal.
— Before a six-week course of clinic visits, exercise is the free first-line move worth exhausting for milder depression.
— TMS is for depression that hasn't budged on therapy and pills — it's an escalation, not a replacement for trying them first.

Substance and claimed effects

Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation technique that uses a focused, time-varying magnetic field generated by a coil placed against the scalp to induce small electrical currents in underlying cortical tissue. The clinical form is repetitive TMS (rTMS), delivered in structured outpatient courses of typically 20–36 daily sessions over 4–6 weeks. Three indications carry US FDA clearance: major depressive disorder when at least one prior antidepressant has failed (NeuroStar 2008, with broader device class clearance since) FDA 2008, deep TMS for obsessive-compulsive disorder (Brainsway Deep TMS, 2018) FDA 2018, and short-term smoking cessation (Brainsway, 2020) FDA 2020. Claimed effects in scope for this entry are: remission/response in treatment-resistant depression (the dominant use case), symptom reduction in OCD, smoking abstinence, the side-effect profile, response durability, and access considerations (cost, time, geography, insurance). The entry covers all of these holistically; lateral indications under active study (PTSD, anxiety disorders, addiction beyond nicotine, chronic pain, neurorehabilitation) are out of scope.

Evidence by addressing question

Mechanism

Science. Magnetic pulses (~1–2.5 Tesla, ~100–300 µs duration) pass unimpeded through skull and induce currents in cortical neurons within ~1.5–3 cm of the coil (figure-8 coils ~1.5 cm; H-coils for deep TMS ~3–4 cm) Rossi et al. 2021. Stimulation frequency dictates direction: high-frequency (10 Hz, "5-second-on, 10-second-off" trains for standard depression protocols) is excitatory and increases cortical excitability; low-frequency (1 Hz, continuous) is inhibitory Lefaucheur et al. 2020. Theta-burst stimulation (TBS) compresses this into a different pattern — bursts of 3 pulses at 50 Hz repeated at 5 Hz; intermittent TBS (iTBS, 600 pulses over ~3 minutes) produces long-term-potentiation-like effects, continuous TBS (cTBS) produces long-term-depression-like effects.

Mechanism (biological). The depression protocol targets the left dorsolateral prefrontal cortex (DLPFC), which is hypoactive in major depression on functional imaging. Excitatory stimulation of left DLPFC modulates downstream limbic circuitry — particularly the subgenual anterior cingulate cortex (sgACC), which is hyperactive in depression — via established fronto-limbic networks. Functional connectivity between the stimulation site and sgACC predicts response; the Cole/Williams Stanford group used individualized fMRI-guided targeting based on this principle to design the SAINT/SNT protocol Cole et al. 2020. OCD protocols target the medial prefrontal cortex and anterior cingulate using H7-coil deep TMS, the network implicated in compulsions Carmi et al. 2019. The smoking cessation protocol stimulates lateral prefrontal cortex and insula, with symptom provocation (cue-exposure) immediately before each session to engage the addiction circuit Zangen et al. 2021.

Downstream neurochemistry: repeated sessions induce changes in BDNF, cortical GABAergic tone, and dopaminergic signaling in striatal targets; the relative contribution of each to clinical response is unsettled. The honest summary is that TMS produces a verifiable physical effect on cortex (motor-evoked potentials, EEG signatures) but the path from "cortical excitability shifted" to "depression remits" is partly inferred.

Evidence (depression)

Science. The pivotal multicenter sham-controlled RCT (O'Reardon et al. 2007, n=301, antidepressant-resistant adults, 4–6 weeks of daily 10 Hz left DLPFC stimulation) showed response rates of ~24% active vs ~12% sham on the MADRS at week 4, with significant separation on Hamilton-D scales — the basis for the 2008 FDA clearance O'Reardon et al. 2007, FDA 2008. The NIMH-funded OPT-TMS trial (George et al. 2010, n=190, treatment-resistant unipolar depression, sham-controlled) confirmed effect with ~14% remission at 3 weeks vs ~5% sham; open-label extension produced ~30% remission George et al. 2010, Lisanby et al. 2009. Meta-analyses pool effect: Berlim et al. 2014 (n=29 trials, 1,371 patients, treatment-resistant) showed response rate ~29% active vs ~10% sham, NNT ≈ 6; remission ~19% vs ~5% Berlim et al. 2014. Brunoni et al. 2017 network meta-analysis ranked bilateral, high-frequency left, and low-frequency right rTMS all superior to sham with effect sizes typical of antidepressants Brunoni et al. 2017. Naturalistic real-world data (Carpenter et al. 2012, n=307 across 42 US clinical sites) showed response ~58% and remission ~37% — higher than RCT averages, attributable to longer treatment courses (~30 sessions) and selection of patients with less severe resistance Carpenter et al. 2012. Theta-burst non-inferiority: the THREE-D trial (Blumberger et al. 2018, n=414, Canadian multicenter) showed iTBS — at ~3 min/session instead of ~37 min — produced equivalent response (~49% vs ~47%) and remission (~32% vs ~27%) compared to standard 10 Hz Blumberger et al. 2018. The Stanford SAINT/SNT trial (Cole et al. 2022, n=29, double-blind sham-controlled) used 10 daily iTBS sessions over 5 days, individualized fMRI-targeted, and produced ~79% remission at week 4 — but with very small n; replication is ongoing Cole et al. 2022. The accelerated protocol won FDA clearance in 2022.

Effect-size comparisons: Mutz et al. 2019 network meta-analysis comparing non-surgical brain stimulation modalities ranked high-dose iTBS and bilateral rTMS among the more effective options behind ECT for major depressive episodes Mutz et al. 2019. Versus pharmacology, the effect sizes for treatment-resistant depression compare favorably to a third antidepressant trial after two failures — STAR*D showed remission rates dropping from ~37% at step 1 to ~14% by step 3 of sequential pharmacology Rush et al. 2006; TMS's ~30% remission in this population is therefore a meaningful step up where pharmacology is hitting diminishing returns.

Practice. CANMAT 2016 lists rTMS as a first-line treatment for adults who fail at least one antidepressant trial Milev et al. 2016. APA-aligned consensus recommendations (McClintock et al. 2018) endorse rTMS for treatment-resistant depression and provide protocol detail; broad European guidelines (Lefaucheur et al. 2020) give Level A evidence for left DLPFC high-frequency stimulation in depression McClintock et al. 2018, Lefaucheur et al. 2020. Medicare and most US commercial payers cover TMS for major depression after documentation of two failed antidepressant trials (typically from different classes) at adequate dose and duration, plus typically one failed psychotherapy course.

Community. Patient-reported outcomes from large clinical networks (Carpenter 2012, Dunner 2014) show satisfaction and effect-size figures consistent with RCT data. Online communities (depression forums, NAMI accounts) report a pattern of "tried everything else first, then TMS worked" — consistent with the indicated population. A counter-thread reports relapse within 6–12 months without maintenance, also consistent with the literature.

Evidence (OCD)

Science. Earlier rTMS-for-OCD trials targeting DLPFC were inconclusive (Mantovani et al. 2010 showed promise in treatment-resistant OCD with low-frequency right DLPFC, n=21) Mantovani et al. 2010. The 2018 FDA OCD clearance was based on Carmi et al. 2019, a multicenter randomized double-blind sham-controlled trial (n=99) of deep TMS using the H7 coil targeting medial prefrontal/anterior cingulate cortex, delivered with personalized symptom provocation immediately before stimulation. Response (≥30% Y-BOCS reduction) was 38% active vs 11% sham; mean Y-BOCS reduction ~6 points vs ~3 points Carmi et al. 2019, FDA 2018. Protocol: 29 daily sessions over ~6 weeks plus a maintenance phase. Effect sizes are smaller than for depression and remission is uncommon; the typical outcome is partial response sustained for months in roughly a third of treated patients.

Practice. OCD TMS access is much more limited than depression TMS — fewer clinics offer it, and insurance coverage is patchy and often requires demonstration of multiple failed SSRI trials plus exposure-response prevention (ERP) therapy. ERP remains the first-line psychotherapy; TMS is positioned as augmentation for treatment-resistant OCD, not a replacement.

Evidence (smoking cessation)

Science. The pivotal multicenter sham-controlled RCT (Zangen et al. 2021, n=262 chronic smokers ≥10 cigarettes/day with prior failed quit attempts) delivered 18 daily deep TMS sessions over 6 weeks (H4-coil bilateral lateral prefrontal and insula targeting, with smoking-cue provocation immediately before each session), then weekly maintenance for 12 weeks. The primary endpoint — 4-week continuous quit rate during weeks 15–18 — was 28% active vs 11.7% sham (p<0.01). At 6 months from start, 19.4% active vs 8.7% sham were continuously abstinent Zangen et al. 2021, FDA 2020. Effect sizes are clinically meaningful — comparable to or exceeding varenicline in this hard-to-treat population. Real-world deployment of smoking-cessation TMS is still very limited; very few US clinics offer it as of mid-decade.

Evidence (other indications)

Not FDA-cleared but actively studied: PTSD (Lefaucheur 2020 Level B), generalized anxiety, chronic neuropathic pain (Level A for motor cortex stimulation), substance use beyond nicotine, post-stroke aphasia and motor rehabilitation, tinnitus. None of these rise to standard-of-care; many showed early-trial signal that didn't replicate cleanly. Out of scope for this entry — flagged as candidates for future entries.

Protocol

Standard 10 Hz depression protocol (NeuroStar and similar figure-8 systems): one session daily, Monday–Friday, for 4–6 weeks (typically 30–36 sessions total). Each session ~37.5 minutes. Patient sits in a reclining chair, awake, no anesthesia. Motor threshold is determined first (the pulse intensity that produces a visible thumb twitch when applied over motor cortex); treatment intensity is 120% of motor threshold. Coil placed over left DLPFC (typically located using the "5 cm rule" anterior to motor hotspot, or via 10–20 EEG F3, or via fMRI/MRI-guided neuronavigation in research centers). 3000 pulses per session typical. After-session: patient drives self home, returns to work.

iTBS depression protocol: identical schedule (daily, 4–6 weeks) but sessions are ~3 minutes — 600 pulses delivered as 2-second trains every 10 seconds. Demonstrated non-inferior to 10 Hz Blumberger et al. 2018; clinics increasingly default to iTBS for throughput reasons.

SAINT/SNT accelerated protocol: 10 iTBS sessions per day separated by ~50 minutes, for 5 consecutive days (50 sessions total in one week). fMRI-guided targeting of the area of left DLPFC most functionally anticorrelated with sgACC, individualized per patient. Approved for treatment-resistant depression 2022; access still limited to a small number of centers Cole et al. 2020, Cole et al. 2022.

OCD protocol: 29 daily deep TMS sessions over ~6 weeks. Patient first elicits OCD symptoms via personalized provocation (e.g., contamination thought, ordering disturbance) for ~3 minutes; the stimulation then runs ~18 minutes over medial prefrontal/anterior cingulate via H7 coil Carmi et al. 2019.

Smoking protocol: 18 daily deep TMS sessions over 6 weeks, with smoking-cue provocation before each session (showing the patient smoking imagery for ~3 minutes), then weekly maintenance for 12 weeks. H4 coil Zangen et al. 2021.

Contraindications

Science / Practice. The dominant absolute contraindication is implanted ferromagnetic or active medical devices in the head/neck region — cochlear implants, deep brain stimulators, vagal nerve stimulators, aneurysm clips, certain ocular implants, cranial metal that could move or heat. Cardiac pacemakers and ICDs are not absolute contraindications for standard rTMS (the field falls off rapidly with distance) but require coordination with cardiology. Pregnancy: deep TMS labels caution; standard TMS is broadly considered safe across pregnancy but data is limited and most clinicians use shared decision-making Rossi et al. 2021.

The headline risk is seizure. Modern estimates put incidence at roughly 1 per 30,000 sessions or 1 per 1,000 patients across a treatment course — markedly lower than early estimates because the 2009 Rossi safety guidelines codified pulse-frequency / intensity / inter-train interval limits that prevent kindling. The 2021 update reports that with adherence to current dosing, seizures are rare and typically occur in patients with additional risk factors (alcohol withdrawal, sleep deprivation, certain medications that lower seizure threshold like bupropion at high doses, clozapine) Rossi et al. 2021. History of epilepsy is a relative contraindication, not absolute; many epilepsy patients have safely received TMS.

Common nuisance side effects: scalp discomfort at the stimulation site (30–40% of patients), headache (30%), facial muscle twitching (transient, during stimulation), lightheadedness. These typically attenuate over the first week. Notably absent: cognitive side effects (no memory impairment, in clear contrast to ECT), sedation, weight gain, sexual dysfunction.

Misconceptions

The most common misconception is conflation with ECT (electroconvulsive therapy). The two share "we apply electricity to your brain for depression" at surface level and nothing else operationally: ECT requires general anesthesia, induces a controlled seizure, causes acute and (some) persistent cognitive side effects, has roughly twice the acute remission rate, and is the standard of care for severe / catatonic / suicidal depression. TMS requires no anesthesia, deliberately stays sub-seizure-threshold, has no cognitive side effects, lower acute remission, and is the standard for treatment-resistant outpatient depression that isn't urgent Mutz et al. 2019.

Second misconception: that TMS is experimental or unproven. It carries FDA clearance for three indications, multiple guideline endorsements, and is reimbursed by Medicare and most major insurers for depression — this is established medicine. Confusion stems from limited public awareness and from many clinicians (primary care, even general psychiatrists) not yet routinely discussing it as an option.

Third: that the patient is unconscious or sedated during sessions. Patients are fully awake, can talk, read, watch video, and drive themselves home. The session feels like rhythmic tapping on the scalp.

Fourth (community): that newer-is-always-better and accelerated SAINT-style protocols dominate standard. The accelerated approach is promising but the high remission rates come from a small early trial with intensive screening; standard daily iTBS or 10 Hz remains the well-replicated workhorse, with accelerated protocols a reasonable choice when timing matters (acute suicidality, patient cannot do a 6-week course).

Audience

The indicated and reimbursable population for depression is adults (18+) with major depressive disorder who have failed at least one (insurance often requires two) prior antidepressant trial at adequate dose and duration. Children and adolescents: emerging evidence; small trials in adolescents (Croarkin 2021) suggest safety and effect signal but with smaller samples; coverage is generally not available for under-18 Croarkin et al. 2021. Older adults respond — though with somewhat lower response rates, particularly above age 60 — and modern protocols (higher dose, longer course) have narrowed but not eliminated this gap Lisanby et al. 2009. OCD audience: adults with treatment-resistant OCD who have failed ERP + SSRI trials. Smoking cessation audience: adults ≥22 (per FDA label) with chronic smoking and prior failed quit attempts.

Alternatives

For treatment-resistant depression, the realistic ladder once two or more antidepressants have failed:

Augmentation pharmacology — lithium, atypical antipsychotic (aripiprazole, brexpiprazole, quetiapine), T3 thyroid hormone, esketamine. Each adds metabolic / endocrine / dissociative side-effect burden.
Ketamine / esketamine (Spravato) — rapid onset (hours-days), modest durability without re-dosing, dissociation during administration, abuse liability concerns. Network meta-analyses suggest comparable acute effect size to TMS in TRD.
ECT — highest acute efficacy (~60–70% remission) but the cognitive cost, anesthesia, and stigma push it to later in the ladder for most patients Mutz et al. 2019.
Psychotherapy intensification — CBT, behavioral activation; lower acute effect than biological options but durable.

Versus all four, TMS occupies a particular slot: comparable or somewhat smaller acute effect than ketamine and ECT, larger than another antidepressant trial, no anesthesia, no cognitive side effects, no abuse liability, the inconvenience cost is daily clinic attendance for 4–6 weeks. For OCD: ERP first, SSRI second, clomipramine third, augmentation fourth, TMS fifth, surgery (anterior capsulotomy, DBS) sixth. For smoking: varenicline, NRT combinations, bupropion, behavioral therapy first; TMS sits at the back of the ladder.

Failure-modes

Common pattern: response without remission (symptoms drop 30–50% but don't reach the diagnostic threshold for remission), followed by gradual return of symptoms over months. The literature shows roughly 50% of acute responders relapse within 12 months without any maintenance strategy Dunner et al. 2014, Janicak et al. 2010. Re-induction (a fresh course) is the typical response and most insurers cover re-induction after documented relapse. Maintenance strategies — periodic single sessions, taper schedules — have less consistent evidence; clinical practice varies. Mantovani et al. 2013 reported that responders maintained on continuation pharmacology had ~50% durable response at 6 months Mantovani et al. 2013. A second failure mode is the under-dosed course: insurance approval for 20 sessions when the patient actually needs 30; clinics that taper sessions when symptoms improve mid-course rather than completing the full course. Real-world data shows clearer outcomes with longer courses (Carpenter 2012) Carpenter et al. 2012.

Third failure mode: targeting / coil-position drift over a 6-week course. Standard "5 cm rule" targeting can miss the optimal DLPFC site by 1–2 cm in patients with atypical neuroanatomy. fMRI-guided neuronavigation reduces this variance but is not yet standard outside research-affiliated clinics. Daily re-positioning by technician introduces some session-to-session variability that may explain why naturalistic effects don't always match best-RCT effects.

Practicalities

Cost. A full depression course of ~36 standard-10-Hz sessions billed at ~$300–500/session (varies by region; iTBS sometimes billed lower because shorter) is roughly $10,000–18,000 sticker price. With insurance coverage for treatment-resistant depression, patient out-of-pocket is typically copays only — for many patients, $0–$2,000 total. Insurance approval requires documented adequate trials of 2+ antidepressants (different classes), a clinician letter, and often one failed psychotherapy course. OCD coverage exists but is more variable; smoking cessation TMS is largely cash-pay.

Time. Standard 10 Hz course: ~37.5 min/session + travel + waiting, daily M-F for 4–6 weeks. Realistically, this consumes about an hour of a working day. iTBS course: ~3 min in the chair, but still daily clinic visits — overall time burden ~30–45 min/day including travel. SAINT/SNT: 5 days totally devoted to the protocol, ~10 hours/day at the clinic.

Geography. Concentrated in mid-to-large urban centers with academic psychiatry or larger private practices. Rural and small-city access remains thin; even modest metros may have only 1–2 providers, creating wait-list bottlenecks.

The session itself. Patient sits in a chair similar to a dental chair. Coil positioned and held in place. Stimulation begins — rhythmic tapping/clicking sound (around 100 dB; earplugs are provided) and a tapping sensation on the scalp. Sessions are loud but otherwise undemanding. Patients can listen to podcasts or music with bone-conduction headphones or low-volume earbuds outside the stimulation window.

History

The motor-evoked-potential paradigm (single-pulse TMS to map motor cortex) was demonstrated by Anthony Barker's group in Sheffield in 1985 — single pulses, no clinical aim. Repetitive TMS emerged in the early 1990s. The first FDA clearance came in 2008 (NeuroStar, depression) FDA 2008. Deep TMS (Brainsway H-coils) received first depression clearance in 2013; OCD in 2018 FDA 2018; smoking cessation in 2020 FDA 2020. Theta-burst protocols moved from research to clinical use after the Blumberger 2018 non-inferiority trial. Accelerated SAINT/SNT cleared FDA in 2022.

Stakes and payoff

Stakes: in the indicated population (treatment-resistant depression specifically), continuing the ladder of medication trials at this point is a low-yield game — STAR*D's step-3 and step-4 remission rates dropped to ~14% and ~13% respectively Rush et al. 2006. The reader who has been on three antidepressants for several years has a substantial probability of still being depressed in another two years. Payoff: durable remission in ~30–40% of those treated, partial response in another ~20–30%; for the subset who reaches remission, the magnitude of the change is the difference between "function is broken" and "function is intact." OCD and smoking payoffs are smaller in magnitude but real — for smoking, ~20% continuous abstinence at 6 months in a population with prior failed quit attempts is a meaningful additional shot.

Credibility range

Optimist case. TMS is settled medicine for treatment-resistant depression. It has FDA clearance from 2008; multiple positive sham-controlled RCTs; large naturalistic series showing real-world effectiveness; CANMAT, European, and APA-aligned consensus endorsements; broad insurance coverage; a clean side-effect profile that compares favorably to all alternatives (no anesthesia, no cognitive cost, no metabolic burden, no abuse liability, no sexual side effects). Acute remission ~30% in patients for whom each subsequent antidepressant trial has ~14% remission means TMS is the highest-yield option remaining in the ladder before ECT — which has higher remission but a much steeper side-effect price. The OCD signal (Carmi 2019) is replicated in a properly powered sham-controlled multicenter trial. The smoking signal (Zangen 2021) is the same. The SAINT/SNT accelerated protocol points toward dramatically higher remission rates in less time when targeting is individualized. The mechanism — modulation of fronto-limbic networks via cortical stimulation — has direct fMRI confirmation. The dominant "loss" to a patient who tries TMS is time and inconvenience; the dominant "gain" if they're a responder is a categorically different baseline.

Skeptic case. Sham TMS is hard. The clicking sound and scalp sensation of real stimulation are not perfectly mimicked by sham coils; blinding has been imperfect in several pivotal trials, which inflates apparent effect via expectancy. The placebo response in depression trials is large in general (sham response rates 25–35% are routine), making the active-sham gap modest in absolute terms. Naturalistic effectiveness (~58% response in Carpenter 2012) is much higher than RCT effectiveness (~29% response in Berlim meta-analysis), suggesting selection effects and regression to mean in real-world data. Response durability is poor: ~50% relapse within a year without maintenance, and what "maintenance" looks like is not well evidence-based. The SAINT remission figures (~79%) come from very small samples (n=29 in the 2022 sham-controlled trial) and are likely to attenuate with replication; independent replications are still scarce. For OCD the effect-size is small in absolute terms (Y-BOCS reduction ~6 points, a Y-BOCS responder typically still has significant OCD); for smoking, effect sizes are comparable to varenicline but with vastly higher access friction. Cost-effectiveness is debated: $10,000+ per course, with high relapse, may compare unfavorably to repeated pharmacology cycles. Major confounders in observational data: TMS patients are highly motivated (they show up daily for 6 weeks), educated, insured — none of this generalizes cleanly to broader populations.

Author's call. Land on the optimist side for treatment-resistant depression specifically — the evidence is solid (multiple positive RCTs, regulatory clearance, guideline endorsement, replicated effect sizes), the mechanism is plausible and partially verified, the side-effect profile is genuinely better than every alternative at this point in the ladder, and the population (treatment-resistant adults with diminishing returns from further pharmacology) is precisely the population for which the modest effect size is most valuable. For OCD: cautiously positive — real signal in a properly designed pivotal trial, but smaller effect size and less robust replication outside the registration trial; positioned as augmentation, not primary. For smoking cessation: real signal but limited access; honest framing is "another tool, not a game-changer." The skeptic case rightly tempers the SAINT-protocol hype and the durability picture — both should be flagged in the article. Evidence: 4 (multiple positive RCTs, broad guideline endorsement, regulatory clearance — but with the small remission-vs-sham gap honestly named). Controversy: 2 (real disagreement on accelerated protocols, durability, and effect-size inflation in naturalistic data — but no foundational dispute about whether it works).

Stakeholder and incentive map

Commercial. Device manufacturers (Neuronetics/NeuroStar, Brainsway, MagVenture, MagStim, Nexstim). Strong incentive to push protocol expansion and indication broadening. TMS clinic chains (NeuroStim TMS, Greenbrook TMS Therapy) operate franchise-style. Both have an incentive to advertise the optimistic effect-size and downplay durability problems.
Professional. Academic neurostimulation societies (Clinical TMS Society, International Federation of Clinical Neurophysiology). Generally aligned with conservative interpretation of evidence; produce the safety and clinical-application guidelines that anchor practice Rossi et al. 2021, Lefaucheur et al. 2020.
Regulatory / payer. FDA, Medicare/CMS, private insurers. The FDA has been cautious — depression clearance 2008, OCD 2018, smoking 2020 each required dedicated multicenter sham-controlled trials. Medicare coverage came in 2013, after considerable delay. Coverage criteria (two failed antidepressants, adequate dose/duration, prior psychotherapy) limit access but also discipline use to the indicated population.
Competing therapies. Ketamine clinics, ECT programs, the Spravato (intranasal esketamine) supply chain — all compete for the treatment-resistant-depression patient. Each pushes its own efficacy/safety narrative.
Skeptic / counter. Some psychotherapy-oriented clinicians frame TMS as an "easy out" that bypasses upstream psychosocial work; some biological psychiatrists are skeptical of effect size relative to a fresh pharmacology trial. Methodologists have raised concerns about sham-blinding integrity, the placebo magnitude, and the gap between trial and naturalistic data.

Population variability

Severity. Better response in moderate-severity treatment-resistant depression than in severe melancholic/psychotic presentations (the latter remain ECT territory). Inadequate-but-not-failed responders to medications also respond to TMS adjunct.
Age. Adolescent and young-adult trials show signal but smaller evidence base Croarkin et al. 2021. Older adults (60+) historically had lower response rates because of cortical atrophy increasing scalp-to-cortex distance; this has been partly addressed by higher-intensity protocols and adjusted coil positioning.
Prior treatment history. Patients with fewer prior failed antidepressant trials (Stage 1–2 resistance) respond more robustly than patients with multiple prior failures (Stage 4+) Lisanby et al. 2009. Voigt et al. 2019 in non-treatment-resistant patients also showed signal, supporting earlier deployment, but this isn't where current US coverage is positioned Voigt et al. 2019.
Comorbid anxiety. Doesn't appreciably reduce depression response.
Bipolar. Bipolar depression has signal but with theoretical mania-induction risk; protocols typically use low-frequency right DLPFC instead of high-frequency left to mitigate.
Smokers / heavy alcohol. Higher seizure risk; smoking cessation TMS is paradoxically the indication that recruits smokers, with no excess seizures reported in the registration trial.

Knowledge gaps

Long-term durability beyond 12 months is poorly characterized — most maintenance studies run 6 months or less. Predictors of response remain investigational (genetic markers, fMRI connectivity patterns, EEG signatures); we cannot yet tell a given patient with confidence whether they will respond. Optimal maintenance protocol — frequency, density, taper — has no clear evidence-based answer. The SAINT/SNT remission figures need independent replication beyond Stanford. Sham-blinding integrity is methodologically still imperfect; better sham designs (low-intensity active stimulation matched for scalp sensation) are being developed but not yet standard. The translation of single-pulse cortical effects to multi-session network-level clinical effects is incompletely understood; mechanism research lags clinical adoption. Comparative-effectiveness against ketamine/esketamine in head-to-head trials is sparse; most patients receive both in sequence rather than randomly assigned. Generalizability beyond the indicated populations (depression, OCD, smoking) is open: PTSD and chronic pain show signal but neither has FDA clearance and trial data is heterogeneous.

Scope coverage vs the brief. The brief named treatment-resistant depression, OCD, smoking cessation, side-effect profile, response durability, and access considerations. All six are covered end to end in the article — TRD is the centre of gravity (it's where the evidence and the indicated audience are strongest), OCD and smoking get smaller but proportionate treatment in evidence/protocol/audience/payoff/out-of-scope. No silent narrowing.

What was excluded and why.

Off-label and emerging indications (PTSD, generalized anxiety, addiction beyond nicotine, chronic neuropathic pain, post-stroke rehabilitation, tinnitus, adolescent depression specifics). Real research base for several but no FDA clearance, no consistent guideline endorsement, and the evidence is too heterogeneous to do honestly inside this entry. Flagged for separate entries as the literature matures.
Detailed mechanism neurochemistry (BDNF, GABAergic tone, dopamine release in striatal targets) — present in the research dossier but compressed in the article to "modulates downstream emotion circuits" because the molecular detail isn't load-bearing for any reader decision.
Specific device-brand comparisons (NeuroStar vs Brainsway vs MagVenture vs MagStim) — declined to name preferences. The clinical literature doesn't show meaningful between-device effect differences for the same protocol, and naming preferences would read as endorsement.

Hard scoring calls.

Evidence: 4 not 5. Multiple positive sham-controlled RCTs, three FDA clearances, broad guideline endorsement (Milev 2016 CANMAT, Lefaucheur 2020, McClintock 2018). What kept it off 5: sham-blinding integrity is methodologically imperfect (real-vs-sham scalp sensation differs), absolute effect sizes are modest, and the OCD / smoking literatures rest on single pivotal trials rather than the multi-RCT base depression has. The 5-tier anchor ("multiple large RCTs or equivalent (Cochrane-level), consistent") is met for depression specifically; averaging the substance holistically lands at 4.
health_short_term: 3. Defensible because the substance produces a substantial functional change in the indicated population (TRD responders); the score is per the substance, not per the median reader. Could be argued at 2 if one weighted the non-responder subset more heavily.
longevity and sleep: 0. Considered 1 for both (indirect via depression remission) and decided against. TMS-specific longevity outcomes aren't measured, and any sleep effect is downstream of mood remission rather than a direct sleep-architecture effect. Honest call per meta §5a — don't score from a plausible-mechanism prior when the dossier hasn't earned it.
controversy: 2. Real but bounded — disagreement on accelerated SAINT/SNT protocols, durability picture, and trial-vs-naturalistic effect-size gap, but no foundational dispute that TMS works for the indicated patient.
cost_burden: 3. The score reflects sticker price; the pitch and article body translate honestly that insurance covers most of it for the indicated patient. Could be argued 2 if scoring post-insurance reality.

Contraindications vocabulary gap. The closed contraindications vocabulary lacks tokens for the dominant TMS-specific issues — implanted-ferromagnetic-device and seizure-history are absent. Only pregnancy was tagged, which understates the practical screening list. These are captured in the article's warning callout, but the structured tag layer is incomplete. Worth proposing token additions.

Action / cadence call. action: decide rather than do — TMS requires a prescriber, screening, and insurance approval; it's a deliberate decision, not a habit to start. cadence: course reflects the time-limited 4–6 week structure with a defined endpoint.

Category call. Placed in medical (Medical & Healthcare) rather than mental (Mental & Cognitive). TMS is a device-based clinical procedure delivered in outpatient courses; the medical bucket fits how a reader would browse to it. Cross-link from a future mental-category overview of treatment-resistant depression would close the loop.

Future-link candidates (entries to cross-link once they exist):

ECT (electroconvulsive therapy) — the closest comparator; explicitly contrasted in the misconceptions and out-of-scope sections.
Ketamine / esketamine (Spravato) for treatment-resistant depression — the other modern non-pharmacology-only option in this slot.
Varenicline / nicotine replacement / smoking-cessation pharmacotherapy — referenced as the first-line for smokers; smoking-TMS only makes sense in the back of that ladder.
Exposure-response prevention therapy for OCD — the first-line that TMS-for-OCD augments.
Treatment-resistant depression as a meta-entry — would benefit from a dedicated overview that this entry links into.

Separate-entry candidates surfaced during research.

Deep brain stimulation (DBS) for OCD / depression — invasive neurostimulation, distinct enough to warrant its own entry.
tDCS (transcranial direct-current stimulation) — a related but distinct non-invasive modality with weaker evidence; should not be conflated with TMS.
The depression treatment ladder as an editorial overview — would make this entry, the antidepressants entries, the ketamine entry, and the ECT entry sit more legibly together.